Recruiting OBSERVATIONAL NCT06461351

Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

A Long Term Follow-up Observational Study of Patients Treated With Inaticabtagene Autoleucel Injection

Sponsor: Juventas Cell Therapy Ltd.

Interventions Inaticabtagene autoleucel Injection

Updated 3 times since 2024 Last updated: Aug 6, 2025 Started: Mar 30, 2024 Primary completion: May 30, 2039 Completion: Mar 30, 2040

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06461351, this observational or N/A phase trial focuses on B-cell Tumors and remains actively recruiting participants. Sponsored by Juventas Cell Therapy Ltd., it has been updated 3 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Recruiting

Status: Active Not Recruiting → Recruiting
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting

First recorded

Mar 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Juventas Cell Therapy Ltd.

Data source: Juventas Cell Therapy Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China